eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | tuberous sclerosis |
| Symptom | C0004114|astrocytoma |
| Sentences | 24 |
| PubMedID- 24708766 | The rapamycin analogs cci-779 (temsirolimus) and rad001 (everolimus) are approved for the clinical treatment of advanced renal cell carcinoma , progressive neuroendocrine tumors of pancreatic origin , subependymal giant cell astrocytoma associated with tuberous sclerosis , and more recently for postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with the aromatase inhibitor exemestane . |
| PubMedID- 22408430 | Likewise, everolimus was approved by fda for the treatment of progressive endocrine tumours of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease and for patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (ts) (http://www.fda.gov). |
| PubMedID- 22654497 | Retinal astrocytoma associated with tuberous sclerosis complex is a relatively static lesion with little potential for aggressive behavior. |
| PubMedID- 25682485 | Conclusion: everolimus is a promising pharmacological approach to treat clinically significant inoperable cardiac rhabdomyomas or subependymal giant cell astrocytoma associated with tuberous sclerosis complex during the neonatal period. |
| PubMedID- 23138436 | Subependymal giant cell astrocytoma associated with tuberous sclerosis presenting with intratumoral bleeding. |
| PubMedID- 23391693 | Management of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc): clinical recommendations. |
| PubMedID- 23183057 | The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. |
| PubMedID- 25143481 | Everolimus treatment for an early infantile subependymal giant cell astrocytoma with tuberous sclerosis complex. |
| PubMedID- 24244540 | Everolimus has been approved for second-line therapy of patients with renal cell carcinoma after failure of treatment with sunitinib and for the treatment of papillary renal carcinoma, pancreatic neuroendocrine tumor, some types of breast cancer, and subependymal giant cell astrocytoma associated with tuberous sclerosis –. |
| PubMedID- 24667713 | Everolimus has demonstrated substantial clinical benefit in randomized, controlled, phase iii studies leading to approval for the treatment of advanced renal cell carcinoma, advanced neuroendocrine tumors of pancreatic origin, renal angiomyolipoma and subependymal giant-cell astrocytoma associated with tuberous sclerosis complex, as well as advanced hormone-receptor-positive (hr(+)) and human epidermal growth factor receptor-2-negative advanced breast cancer. |
| PubMedID- 22805244 | Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 20422196 | The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. |
| PubMedID- 24756805 | Everolimus has been approved by the fda and the ema for the treatment of advanced renal cell carcinoma (rcc), subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (tsc), pancreatic neuroendocrine tumors (pnet), in combination with exemestane in advanced hormone-receptor (hr)-positive, her2-negative breast cancer. |
| PubMedID- 25456370 | Background: in the exist-1 trial, initiated on aug 10, 2009, more than 35% of patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex had at least 50% reduction in sega volume after 9.6 months of treatment with everolimus. |
| PubMedID- 23229407 | Neuro-oncology: everolimus for astrocytoma in tuberous sclerosis complex. |
| PubMedID- 23325902 | Objective: to report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (sega) in patients with tuberous sclerosis complex (tsc). |
| PubMedID- 24757527 | Everolimus is effective in the treatment of large angiomiolypomas (aml) in patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc). |
| PubMedID- 23567018 | Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 22234227 | Hemorrhagic subependymal giant cell astrocytoma in a patient with tuberous sclerosis: case report and review of the literature. |
| PubMedID- 23404211 | It is approved for the treatment of patients with progressive neuroendocrine tumors of pancreatic origin, advanced renal cell carcinoma, and subependymal giant cell astrocytoma associated with tuberous sclerosis . |
| PubMedID- 24507694 | Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. |
| PubMedID- 22136276 | Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 23686401 | Everolimus is a mammalian target of rapamycin (mtor) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive her2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole. |
| PubMedID- 24319280 | Objective: this study was aimed to explore parents' experience of assisting children affected by tuberous sclerosis complex (tsc) with subependymal giant-cell astrocytoma (sega) manifestation, in order to understand their caring needs and expectation of support. |
Page: 1